Abstracts Archive - Page 2146 of 2607 - ACR Meeting Abstracts

Abstract Number: 1309 • 2014 ACR/ARHP Annual Meeting
Does Anti-C1q Antibody Have Diagnostic and Prognostic Roles in Childhood – Onset Systemic Lupus Erythematosus?
Thaschawee Arkachaisri¹, Joo Guan Yeo², Justin Hung Tiong Tan³, Sook Fun Hoh⁴, Lena Das³ and Jing Yao Leong², ¹Rheumatology & Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Children Intensive Care Unit (CICU), KK Women's and Children's Hospital, Singapore, Singapore, ³Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ⁴Nursing, KK Women's and Children's Hospital, Singapore, Singapore
Background/Purpose: Biomarkers proven to be effective in aSLE patients may not directly apply to cSLE unless validation is done. Existing evidences have shown immunopathogenic roles…
Abstract Number: 1308 • 2014 ACR/ARHP Annual Meeting
Antinucleosome Antibodies As Potential Diagnostic and Prognostic Biomarkers in Childhood Onset Systemic Lupus Erythematosus
Thaschawee Arkachaisri¹, Joo Guan Yeo², Justin Hung Tiong Tan³, Sook Fun Hoh⁴, Lena Das³ and Jing Yao Leong², ¹Rheumatology & Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Children Intensive Care Unit (CICU), KK Women's and Children's Hospital, Singapore, Singapore, ³Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ⁴Nursing, KK Women's and Children's Hospital, Singapore, Singapore
Background/Purpose: The role of antinucleosome antibodies (ANuA) in the immunopathogenesis of SLE is evident. ANuA was shown to be a good, if not better than…
Abstract Number: 1307 • 2014 ACR/ARHP Annual Meeting
Monitoring of Mid-Interval Plasma Levels of Mycophenolic Acid in Pediatric Lupus Nephritis Patients
Joyce S Hui-Yuen¹, Kristi Truong², Liza Mariel Bermudez-Santiago¹, Amy J. Starr³, Andrew Eichenfield⁴, Lisa F. Imundo⁵ and Anca Askanase³, ¹Morgan Stanley Children's Hospital of New York Presbyterian, Columbia University Medical Center, New York, NY, ²Doctor of Pharmacy degree program, St John's University, Queens, NY, ³Columbia University Medical Center, New York, NY, ⁴Div of Pediatric Rheumatology, Children's Hosp of New York, New York, NY, ⁵Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY
Background/Purpose: Mycophenolate mofetil (MMF) is often used to treat lupus nephritis (LN) and extra-renal lupus in children with SLE. Plasma levels of mycophenolic acid (MPA)…
Abstract Number: 1306 • 2014 ACR/ARHP Annual Meeting
Outcome of Lupus Nephritis in Children Less Than 12 Years Old from North-India
Anju Gupta, Bonnie Abujam, Deepti Suri, Amit Rawat and Surjit Singh, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose Studies on lupus nephritis in young children below 12 years of age from developing countries are limited. This study looks at long-term outcome in…
Abstract Number: 1305 • 2014 ACR/ARHP Annual Meeting
Adiposity and Adipokines Are Associated with Insulin Resistance in Pediatric Systemic Lupus Erythematosus
Leandra Uribe Woolnough^1,2, Tracey Wright^2,3 and Gloria Vega⁴, ¹Pediatrics, UT Southwestern Medical Center, Dallas, TX, ²Children's Medical Center, Dallas, TX, ³Pediatrics/Rheumatology, UT Southwestern Medical Center, Dallas, TX, ⁴Center for Human Nutrition, UTSouthwestern Medical Center, Dallas, TX
Background/Purpose: Traditional risk factors for cardiovascular disease do not fully account for the increase in atherosclerosis in SLE. Insulin resistance (IR) and other metabolic derangements…
Abstract Number: 1304 • 2014 ACR/ARHP Annual Meeting
Development of an Index to Non-Invasively Quantify Lupus Nephritis Chronicity in Children
Khalid Abulaban¹, Michael Bennett², Marisa Klein-Gitelman³, Stacy P. Ardoin⁴, Kelly A. Rouster-Stevens⁵, Lori B. Tucker⁶, Kasha Wiley⁷, Shannen Nelson⁸, Karen Onel⁹, Nora G. Singer¹⁰, Kathleen M. O'Neil¹¹, B Anne Eberhard¹², Lawrence K. Jung¹³, Lisa F. Imundo¹⁴, Tracey Wright¹⁵, David Witte¹⁶, Jun Ying¹⁷, Prasad Devarajan² and Hermine I. Brunner¹⁸, ¹Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Anne & Robert H Lurie Childrens Hospital of Chicago, Chicago, IL, ⁴Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, ⁵Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁶Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁷Rheumatology, Cincinnati Children's Hospital Medical Center, c, OH, ⁸Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ¹⁰Medicine, Division of Rhuematology, Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, ¹¹Division of Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ¹²Pediatrics/Rheumatology, Cohen Children's Medical Center, Lake Success, NY, ¹³Pediatric Rheumatology, Children's National Medical Center, Washington, DC, ¹⁴Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY, ¹⁵Pediatrics/Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹⁶Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ¹⁷University of Cincinnati, Cincinnati, OH, ¹⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The current gold standard for assessing chronic changes in Lupus Nephritis (LN) is a kidney biopsy interpreted using the International Societies for Nephrology &…
Abstract Number: 1303 • 2014 ACR/ARHP Annual Meeting
Accuracy of Laboratory Measures and Clinical Renal Activity Indices for Reflecting Biopsy-Proven Lupus Nephritis (LN) Activity
Khalid Abulaban¹, Stacy P. Ardoin², Marisa Klein-Gitelman³, Kelly A. Rouster-Stevens⁴, Michael Bennett⁵, Lori B. Tucker⁶, Kasha Wiley⁷, Shannen Nelson⁸, Karen Onel⁹, Nora G. Singer¹⁰, B Anne Eberhard¹¹, Kathleen M. O'Neil¹², Elizabeth B. Brooks¹³, Lawrence K. Jung¹⁴, Lisa F. Imundo¹⁵, Tracey Wright¹⁶, David Witte¹⁷, Jun Ying¹⁸, Prasad Devarajan⁵ and Hermine I. Brunner¹⁹, ¹Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, ³Anne & Robert H Lurie Childrens Hospital of Chicago, Chicago, IL, ⁴Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁵Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁶Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁷Rheumatology, Cincinnati Children's Hospital Medical Center, c, OH, ⁸Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ¹⁰Medicine, Division of Rhuematology, Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, ¹¹Pediatrics/Rheumatology, Cohen Children's Medical Center, Lake Success, NY, ¹²Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ¹³Pediatric Infectious Disease, Rheumatology and Geographic Medicine, Case Medical Center, Cleveland, OH, ¹⁴Pediatric Rheumatology, Children's National Medical Center, Washington, DC, ¹⁵Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY, ¹⁶Pediatrics/Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹⁷Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ¹⁸University of Cincinnati, Cincinnati, OH, ¹⁹Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose : LN is common in childhood-onset Systemic Lupus Erythematosus (cSLE). Kidney biopsies are impractical to assess the course of LN given their invasiveness and…
Abstract Number: 1321 • 2014 ACR/ARHP Annual Meeting
A Pilot Study to Evaluate the Feasibility of Conducting Juvenile Localized Scleroderma Comparative Effectiveness Treatment Studies
Suzanne C. Li¹, Kathryn S. Torok², Mara L Becker^3,4, Fatma Dedeoglu⁵, Polly J. Ferguson⁶, Robert C. Fuhlbrigge^7,8, Gloria C. Higgins⁹, Sandy D. Hong¹⁰, Maria F. Ibarra¹¹, Ronald Laxer¹², Thomas G. Mason II¹³, Elena Pope¹⁴, Marilynn G. Punaro¹⁵, C. Egla Rabinovich¹⁶, Katie G. Stewart¹⁵ and Brian Feldman¹⁷, ¹Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³Rheumatology, Children's Mercy Hospital, Kansas City, MO, ⁴Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO, ⁵Rheumatology, Boston Children's Hospital, Boston, MA, ⁶Dept of Pediatrics--Rheum, University of Iowa Carver College of Medicine, Iowa City, IA, ⁷Department of Dermatology, Brigham and Women's Hospital, Boston, MA, ⁸Division of Immunology, Boston Children's Hospital, Boston, MA, ⁹Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ¹⁰Pediatrics-Rheumatology, U of Iowa Children's Hosp, Iowa City, IA, ¹¹Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ¹²Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ¹³Rheumatology, Mayo Clinic Rochester, Rochester, MN, ¹⁴Dermatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁵Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹⁶Pediatric Rheumatology, Duke Univ Med Ctr, Durham, NC, ¹⁷Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose Juvenile localized scleroderma (jLS) often causes severe morbidity in the developing child, including growth defects and disfigurement. Optimal therapy is not known. The…
Abstract Number: 1320 • 2014 ACR/ARHP Annual Meeting
Analysis of Risk Factors for Thrombosis in Pediatric Patients with Systemic Lupus Erythematosus
Kyla D. Driest¹, Mollie S. Sturm², Sarah H. O'Brien³, Charles H. Spencer⁴ and Stacy P. Ardoin⁵, ¹Rheumatology, OSU Pediatrics, Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Hematology, Nationwide Children's Hospital, Columbus, OH, ⁴Rheumatology, Nationwide Childrens Hospital, Columbus, OH, ⁵Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a higher thrombotic risk compared to the general population, and arterial and venous thromboses impart substantial morbidity…
Abstract Number: 1319 • 2014 ACR/ARHP Annual Meeting
Safety of Rituximab in Treating Pediatric Rheumatologic Disease
Arunima Agarwal¹, Anusha Ramanathan² and Rhina Castillo³, ¹Pediatric Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, ²Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ³Pediatric Rheumatology, Childrens Hospital Los Angeles, Los Angeles, CA
Background/Purpose Rituximab is a chimeric human/murine monoclonal antibody directed against the B cell specific antigen CD20. There is growing evidence that suggests Rituximab may also…
Abstract Number: 1318 • 2014 ACR/ARHP Annual Meeting
Illness Onset Features and Misdiagnosis in Juvenile Idiopathic Inflammatory Myopathies (JIIM) Differ Among Clinical and Autoantibody (Ab) Subgroups
Gulnara Mamyrova¹, Lan Wu², Adam Huber³, Ira N. Targoff⁴, Frederick W. Miller² and Lisa G. Rider², ¹Rheumatology, George Washington University, Washington, DC, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³IWK Health Centre, Halifax, NS, Canada, ⁴Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: To evaluate features of JIIM clinical and Ab subgroups at illness onset. Methods: Physician-completed questionnaires illness onset features were reviewed in 465 JIIM pts…
Abstract Number: 1317 • 2014 ACR/ARHP Annual Meeting
Anti-p155/140 Autoantibodies and Selected Features at Illness Onset Are Associated with a Chronic Course of Illness in the Juvenile Idiopathic Inflammatory Myopathies
G. Esther A. Habers¹, Adam M. Huber², Gulnara Mamyrova³, Ira Targoff⁴, Chantal Boonacker⁵, Marco van Brussel¹, Frederick W. Miller⁶, Lisa G. Rider⁶ and Annet van Royen-Kerkhof⁷, ¹Child Development and Exercise Center, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands, ²IWK Health Centre, Halifax, NS, Canada, ³Rheumatology, George Washington University, Washington, DC, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁷Paediatric Immunology and Rheumatology, University Medical Centre Utrecht - Wilhelmina Children's Hospital, Utrecht, Netherlands
Background/Purpose : Three types of disease courses can be distinguished in patients with juvenile idiopathic inflammatory myopathies (JIIM), namely monocyclic (M), polycyclic (P), and chronic…
Abstract Number: 1316 • 2014 ACR/ARHP Annual Meeting
A Hybrid Conjoint Analysis Model Is Proposed As the Definition of Minimal, Moderate and Major Clinical Improvement in Juvenile Dermatomyositis Clinical Trials
Lisa G. Rider¹, Rohit Aggarwal², Nastaran Bayat¹, Brian Erman³, Brian M. Feldman⁴, Adam M. Huber⁵, Rolando Cimaz⁶, Rubén J. Cuttica⁷, Sheila K. Feitosa de Oliveira⁸, Carol B. Lindsley⁹, Clarissa A Pilkington¹⁰, Marilynn G. Punaro¹¹, Angelo Ravelli¹², Ann M. Reed¹³, Kelly A. Rouster-Stevens¹⁴, Annet van Royen-Kerkhof¹⁵, Luca Villa¹⁶, Mariangela Rinaldi¹⁶, Angela Pistorio¹⁷, Howard Rockette¹⁸, Peter A. Lachenbruch¹, Frederick W. Miller¹, Jiri Vencovsky¹⁹ and Nicolino Ruperto²⁰, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Social and Scientific Systems, Inc., Durham, NC, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵IWK Health Centre, Halifax, NS, Canada, ⁶Pediatrics, University of Firenze, Firenze, Italy, ⁷Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, ⁸Pediatric Rheumatology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ⁹Dept of Pediatrics/ PTD, Univ Kansas City Med Ctr, Kansas City, KS, ¹⁰Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ¹¹Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, ¹²University of Genova, Genova, Italy, ¹³Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴Pediatrics, Emory University School of Medicine, Atlanta, GA, ¹⁵Paediatric Immunology and Rheumatology, University Medical Centre Utrecht - Wilhelmina Children's Hospital, Utrecht, Netherlands, ¹⁶Pediatria II, Reumatologia, PRINTO, IRCCS Istituto G. Gaslini, Genova, Italy, ¹⁷Istituto Giannina Gaslini, Genova, Italy, ¹⁸University of Pittsburgh, Pittsburgh, PA, ¹⁹Institute of Rheumatology, Charles University, Prague, Czech Republic, ²⁰Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Preliminary definitions of improvement (DOIs) for juvenile dermatomyositis (JDM) combining IMACS or PRINTO core set activity measures (CSMs) have been used as a…
Abstract Number: 1315 • 2014 ACR/ARHP Annual Meeting
Cross-Sectional Evaluation of Hydroxychloroquine (HCQ) Therapy in Children with Juvenile Dermatomyositis (JDM) Enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Yonit Sterba¹, Dawn Wahezi² and For the CARRA investigators³, ¹Pediatric Rheumatology, Montefiore Medical Center, Bronx, NY, ²Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ³Duke Children's Hospital, Durham, NC
Background/Purpose: Hydroxychloroquine is an antimalarial agent commonly used in the treatment of rheumatologic diseases. Data on the use of HCQ in JDM is limited, primarily…
Abstract Number: 1301 • 2014 ACR/ARHP Annual Meeting
Trabecular Bone Impairment Assessed By HR-pQCT in Juvenile-Onset Systemic Lupus Erythematous with Vertebral Fractures
Juliane Paupitz, Glauce Lima, Valéria Caparbo, Henrique Fuller, Eloisa Bonfa and Rosa M R Pereira, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose The three-dimensional evaluation of bone by HR-pQCT has the advantage to provide assessment to not only bone density, but also to a noninvasive evaluation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].